HCC Research Reagents: AFP, GPC3, PD-L1 & Immunotherapy Targets

Hepatocellular carcinoma (HCC) is the most common primary liver cancer, with the treatment landscape transformed by the combination of atezolizumab (anti-PD-L1) + bevacizumab (anti-VEGF), which established a new standard of care for advanced HCC. For a broader view of all oncology reagent categories, see our Cancer Research Reagents hub.

Key Targets and Biomarkers

AFP (alpha-fetoprotein) is the classic HCC serum biomarker. Anti-AFP antibodies are used in IHC for histological diagnosis (distinguishing HCC from intrahepatic cholangiocarcinoma) and in ELISA for serum monitoring. For diagnostic panel guidance, see our IHC Panel Design guide.

GPC3 (Glypican-3) is a heparan sulfate proteoglycan overexpressed in HCC but absent in normal liver tissue. GPC3 IHC is used as a diagnostic marker (sensitivity ~70–80% in HCC), and GPC3 is a promising target for ADCs, CAR-T cells, and bispecific antibodies in HCC immunotherapy.

PD-L1 expression in HCC is heterogeneous (5–30% positivity depending on the antibody clone and scoring method). Anti-PD-L1 IHC antibodies enable expression profiling in HCC tissue. The immunosuppressive tumor microenvironment in HCC — enriched with Tregs, MDSCs, and TAMs — is a major focus of combination immunotherapy research.

VEGFR-2 and VEGF-A antibodies support angiogenesis research in HCC, which is one of the most vascular solid tumors. Research biosimilar bevacizumab and atezolizumab are available for PK/ADA assays and preclinical combination studies.

References

1. Hanahan D. Hallmarks of cancer: new dimensions. Cancer Discov. 2022;12(1):31-46. doi: 10.1158/2159-8290.CD-21-1059

2. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252-264. doi: 10.1038/nrc3239

3. Sharma P, Allison JP. The future of immune checkpoint therapy. Science. 2015;348(6230):56-61. doi: 10.1126/science.aaa8172

All products are for research use only. For technical support, contact order@abinscience.com.